Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

This study tests TROP-2-directed treatment; the registry reports that it is recruiting.

Recruiting

The registry lists NCT07101432 as recruiting, last updated 2026-10-05. Enrolment is 33 planned participants, an estimate. Interventions: Fludarabine, Cyclophosphamide. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications. The brief summary specifies TROP2 CAR/IL-15 TGFBR2-knockout cord-blood NK cells with radiation; the intervention list names only the lymphodepleting drugs.

Setting

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Registry

NCT07101432

Started

2025-12-19

Enrolled

Connected

targets

TROP2

Evidence strength4/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Targets

TROP2

Sourced, not expert-reviewedEvery fact here carries a dated source and the automated checks run on every build. Next scheduled re-check 3 February 2027. No named reviewer has signed it off. It is queued for expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT07101432

A source that has moved or gone is reported by the weekly link check. /audit/

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

This study tests TROP-2-directed treatment; the registry reports that it is recruiting.

Recruiting

Setting

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Registry

NCT07101432

Started

2025-12-19

Enrolled

Connected

targets

TROP2

Evidence strength4/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Targets

TROP2

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT07101432

A source that has moved or gone is reported by the weekly link check. /audit/

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

Overview

Connected

targets

Sources

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

Overview

Connected

targets

Sources